Heartsciences receives fda breakthrough device designation for myovista insights ai-ecg algorithm for detecting aortic stenosis

Southlake, tx, june 04, 2025 (globe newswire) -- heartsciences inc. (nasdaq: hscs; hscsw) (“heartsciences” or the “company”), an artificial intelligence (“ai”) powered medical technology company focused on advancing the capabilities of ecgs/ekgs for the earlier detection of heart disease, today announced that the u.s. food and drug administration (“fda”) has granted breakthrough device designation for its aortic stenosis (“as”) ecg algorithm. aortic stenosis is one of the most serious and common heart valve diseases, often progressing silently and leading to severe, life-threatening outcomes if left undetected.
HSCS Ratings Summary
HSCS Quant Ranking